SUZHOU, China, April 1, 2025 /PRNewswire/ -- Today, April 1st, Peijia Medical Technology (Suzhou) Co., Ltd. held a strategic innovation cooperation signing ceremony and a press conference to announce the research and development achievements of polymer heart valves using ultra-high molecular weight polyethylene (UHMWPE) and thermoplastic polyurethane (TPU) from the Biomedical business of dsm-firmenich, innovators in nutrition, health, and beauty, at Peijia Medical's global headquarters. The sign

Following a successful Korea launch, MEPSGEN brings advanced microfluidic technology to U.S. researchers NanoCalibur™ offers precise, scalable, and reproducible nanoparticle production for drug development MEPSGEN's CEO to present new technology at the 4th LNP Formulation & Process Development Summit, on April 15, in Boston. BOSTON, April 1, 2025 /PRNewswire/ -- MEPSGEN US Inc., a global innovator in scalable nanoparticle production technology, announced today the launch of NanoCalibur™, a cutt

ELK GROVE VILLAGE, Ill., April 1, 2025 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, has been selected by Neurotech Pharmaceuticals, Inc., as the exclusive specialty pharmacy partner for ENCELTO™ (revakinagene taroretcel-lwey), an FDA-approved encapsulated cell therapy implant for the treatment of Macular Telangiectasia type 2 (MacTel). [For more information, see Neurotech's ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiect

CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC: MRZM). Qualigen and Marizyme have entered an MOU dated March 28, 2025. This is the logical next step in acquiring Marizyme, following on our co-marketing agreement established in 2024. Upon completion of full due diligence, we will proceed with the final structure and deal ter

News Summary Boosts out-of-the-box sensitivity by up to 80 times with MaxPeakTM Premier columns.1 Delivers over threefold improvements in day-to-day reproducibility2 and decreases carryover by up to two orders of magnitude.3 Reduces common user errors by up to 40%.4 MILFORD, Mass., April 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the expansion of the Alliance™ iS Bio HPLC product line with integrated photodiode array (PDA) detection, advancing the capabilities of t

“Pimicotinib represents a key advancement within the emerging class of CSF-1R inhibitors,” Abbisko Therapeutics CEO Yao-Chang Xu said.\n With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug.The German pharma originally paid $70 million for the greater China commercialization rights back in 2023, while retaining an option to expand its interest to cover the rest of the world.

COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results.Business highlights2024 and the first months of 2025 saw Evaxion make substantial progress in both business development, research and development and financing. Key highlights are listed below.Our transformational partnership with MSD (Merck Sharp &

Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study PopulationPURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results from the Phase 2 SHINE (COG0201) study of zervimesine (CT1812) in mild-to-moderate Alzheimer’s disease at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Con

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that further to its press release dated March 3, 2025, it has entered into an asset purchase agreement (the “Agreement”) dated March 31, 2025 with DiagnaMed Holdings Corp. (CS

Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercialization of Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) DUBLIN, Ireland and OXFORD, United Kingdom, April 01, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for